Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CCL17 Biologics Sequence Review Report 2026: C-C motif chemokine 17 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL13 Biologics Sequence Review Report 2026: C-C motif chemokine 13 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL13 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
PDGFRA Biologics Sequence Review Report 2026: Platelet-derived growth factor receptor alpha Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of PDGFRA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
IL6ST Biologics Sequence Review Report 2026: Interleukin-6 receptor subunit beta Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of IL6ST protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
PDGFRB Biologics Sequence Review Report 2026: Platelet-derived growth factor receptor beta Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of PDGFRB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FLT4 Biologics Sequence Review Report 2026: Vascular endothelial growth factor receptor 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of FLT4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FLT1 Biologics Sequence Review Report 2026: Vascular endothelial growth factor receptor 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of FLT1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHB2 Biologics Sequence Review Report 2026: Ephrin type-B receptor 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHB3 Biologics Sequence Review Report 2026: Ephrin type-B receptor 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHB4 Biologics Sequence Review Report 2026: Ephrin type-B receptor 4 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHB4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHB1 Biologics Sequence Review Report 2026: Ephrin type-B receptor 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA8 Biologics Sequence Review Report 2026: Ephrin type-A receptor 8 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.